View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
April 27, 2022

Citius enrols first subject in Phase IIb trial of Halo-Lido for haemorrhoids

The company anticipates results from the trial of Halo-Lido in the second half of next year.

Citius Pharmaceuticals has enrolled the first subject in the Phase IIb clinical trial of its therapy Halo-Lido to treat haemorrhoids. 

The company anticipates results from the trial in the second half of next year.

A topical formulation of halobetasol and lidocaine, Halo-Lido is designed to offer symptomatic relief to people with haemorrhoids. 

On securing the US Food and Drug Administration (FDA) approval, Halo-Lido could become the first prescription product indicated to treat haemorrhoids.

The double-blind, randomised, multicentre, dose-ranging, parallel-group comparison trial will have five cohorts of adult subjects with symptomatic Goligher’s classification Grade II or Grade III haemorrhoids. 

It will enol a total of 300 subjects with nearly 60 subjects in each cohort.

Assessing the ability of the formulations of Halo-Lido used in each cohort to offer relief to trial subjects with acute flare-ups is the main goal of the trial. 

Furthermore, the trial will assess the decline in haemorrhoidal symptoms including pain, burning, itching, and swelling on receiving Halo-Lido as the primary endpoint.

It is intended to offer the foundation for the development of the Phase III trial. 

Citius Pharmaceuticals executive chairman Leonard Mazur said: “We are pleased to have initiated the Halo-Lido study and expect to complete enrolment later this year. 

“Currently, there are no FDA-approved prescription-strength treatments available to the millions of adults who suffer from haemorrhoid discomfort each year. 

“Assuming study results are positive, and in order to realise the full potential of Halo-Lido, we intend to seek strategic or financial partners for this asset at the appropriate time.”

Haemorrhoid is a gastrointestinal disorder that causes pain, swelling, itching, tenderness and bleeding.

The company enrolled the first patient in a Phase III trial of Mino-Loktherapy plus systemic antibiotics to treat catheter-related bacteremias (CRBSIs) in February 2018.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy